San Diego, California, USA – April 22, 2026

In a significant development in oncology drug innovation, Phanes Therapeutics has announced that it will present updated Phase 2 clinical trial results for its investigational therapy spevatamig (PT886) in combination with chemotherapy for first-line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) at the upcoming ASCO Annual Meeting 2026 in Chicago. The data presentation marks an important milestone in advancing bispecific antibody-based therapies for one of the most aggressive and difficult-to-treat cancers.

Advancing First-Line Treatment in Metastatic PDAC

The Phase 2 study evaluates spevatamig in combination with gemcitabine and nab-paclitaxel (GnP) as a frontline therapy for patients with Metastatic Pancreatic Ductal Adenocarcinoma, a disease with poor prognosis and limited treatment options. The trial has enrolled a broad patient population, with approximately 180 patients dosed globally across monotherapy and combination settings, reflecting significant clinical progress.

Spevatamig is a first-in-class IgG-like bispecific antibody designed to target claudin 18.2 (CLDN18.2) and CD47, combining tumor-specific targeting with immune system activation. This dual mechanism enables the therapy to enhance tumor cell killing while overcoming immune evasion, addressing key challenges in pancreatic cancer treatment.

The upcoming presentation at ASCO will provide critical insights into efficacy, safety, and response durability, potentially positioning spevatamig as a next-generation therapeutic option in first-line PDAC treatment.

Advertisement

cGxPJobs Banner

Regulatory Recognition and Strategic Collaborations

Spevatamig has already received Orphan Drug Designation (ODD) from the U.S. FDA in 2022 and Fast Track Designation in 2024, highlighting its potential to address a serious condition with significant unmet medical need. These designations support accelerated clinical development and regulatory review, reinforcing confidence in the therapy’s clinical potential.

In addition, Phanes Therapeutics has established a strategic collaboration with Merck (MSD outside the U.S. and Canada) to evaluate spevatamig in combination with pembrolizumab, a widely used immune checkpoint inhibitor. This collaboration reflects a broader strategy to explore combination immunotherapy approaches, which are increasingly recognized as critical for improving outcomes in solid tumors.

The company is also advancing multiple Phase 2 programs, including therapies such as peluntamig and mavrostobart, leveraging its proprietary PACbody®, SPECpair®, and ATACCbody® platforms to develop innovative bispecific antibodies with enhanced efficacy and manufacturability.

Potential Impact on Pancreatic Cancer Treatment Landscape

Pancreatic ductal adenocarcinoma remains one of the deadliest cancers globally, with a five-year survival rate below 10% and limited effective treatment options, particularly in the metastatic setting. Current standard-of-care regimens often provide modest survival benefits, underscoring the urgent need for novel, targeted therapies.

Spevatamig’s dual-targeting mechanism represents a promising advancement in this space, combining precision targeting of tumor antigens with immune modulation to enhance therapeutic outcomes. By addressing both tumor biology and immune suppression, the therapy has the potential to improve response rates and extend survival in a patient population with few alternatives.

The upcoming ASCO presentation is expected to provide critical validation of this approach, offering new insights into how bispecific antibodies can reshape treatment paradigms in oncology. If results continue to demonstrate strong efficacy and safety, spevatamig could emerge as a key contender in frontline PDAC therapy, driving innovation in the treatment of gastrointestinal cancers.

As the oncology field increasingly shifts toward combination therapies and targeted biologics, Phanes Therapeutics’ progress underscores the growing importance of next-generation antibody engineering platforms in addressing complex malignancies. The company’s expanding pipeline and strategic collaborations position it at the forefront of precision oncology innovation, with the potential to deliver meaningful clinical benefits to patients worldwide.

Source: Phanes Therapeutics press release